Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
about
Histone Deacetylases and Their Inhibition in Candida SpeciesEmerging Threats in Antifungal-Resistant Fungal PathogensEvolution and Application of Inteins in Candida species: A ReviewPhotodynamic Inactivation of Candida albicans with Imidazoacridinones: Influence of Irradiance, Photosensitizer Uptake and Reactive Oxygen Species GenerationPhenolic composition and medicinal usage of Psidium guajava Linn.: Antifungal activity or inhibition of virulence?Selective BET bromodomain inhibition as an antifungal therapeutic strategySpecific Human and Candida Cellular Interactions Lead to Controlled or Persistent Infection Outcomes during Granuloma-Like Formation.Weekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.Ppg1, a PP2A-type protein phosphatase, controls filament extension and virulence in Candida albicans.Antifungal Activity of Decyl Gallate against Several Species of Pathogenic Fungi.New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study.Characterising atypical Candida albicans clinical isolates from six third-level hospitals in Bogotá, ColombiaYear in review in Intensive Care Medicine 2014: III. Severe infections, septic shock, healthcare-associated infections, highly resistant bacteria, invasive fungal infections, severe viral infections, Ebola virus disease and paediatrics.Screening the Pathogen Box for Identification of Candida albicans Biofilm InhibitorsEffect of silver nanoparticles on Candida albicans biofilms: an ultrastructural study.Contribution of Candida biomarkers and DNA detection for the diagnosis of invasive candidiasis in ICU patients with severe abdominal conditionsBasis for selecting optimum antibiotic regimens for secondary peritonitis.Drug resistance mechanisms and their regulation in non-albicans Candida species.Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus.Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible Candida albicans infections.Candida albicans Germ-Tube Antibody: Evaluation of a New Automatic Assay for Diagnosing Invasive Candidiasis in ICU Patients.Tolerance to Caspofungin in Candida albicans Is Associated with at Least Three Distinctive Mechanisms That Govern Expression of FKS Genes and Cell Wall Remodeling.Candida species diversity and antifungal susceptibility patterns in oral samples of HIV/AIDS patients in Baja California, Mexico.A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality.[Strategies for antifungal treatment failure in intensive care units].Outcomes associated with routine systemic antifungal therapy in critically ill patients with Candida colonization.β-D-Glucan and Candida albicans germ tube antibody in ICU patients with invasive candidiasis.Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial.Revisiting Species Distribution and Antifungal Susceptibility of Candida Bloodstream Isolates from Latin American Medical Centers.MICAFUNGIN ENHANCES THE HUMAN MACROPHAGE RESPONSE TO Candida albicans THROUGH β-GLUCAN EXPOSURE.Tpd3-Pph21 phosphatase plays a direct role in Sep7 dephosphorylation in Candida albicans.Management of Patients with Oral CandidiasisAnti-Candidal Activity and In Vitro Cytotoxicity Assessment of Graphene Nanoplatelets Decorated with Zinc Oxide Nanorods
P2860
Q26740146-BB2DB6A5-6702-4D9E-88BE-EA03A2ADC7F1Q26750816-9BE0DC3D-4833-41E2-A319-93B59DF7B332Q28078765-B731582A-9964-4C1C-877F-001F457DDD5CQ28547979-30347944-0669-4C94-A1F0-29698F8BDD7DQ28817992-B842A687-0A35-4307-9CE3-AB05E89C855AQ30354737-617512B3-7A35-4914-B2CD-66BF906A5924Q30833475-64203B0A-A71B-484F-B983-B0DCFB02AF6FQ33712955-E7E93C87-5D04-474E-AC43-ED781D6E0DC2Q34592589-2D6706D8-C601-4E63-89A1-C10763434B70Q34645936-30DF4739-F171-4767-85B2-9D0562CA1C2BQ35177179-FA6BDCE6-E11C-4754-838E-F3A31CF7F69CQ35799878-F6F4BEE0-34D2-4523-B575-191A23D2C8EDQ35816268-8CE1B45A-E826-4963-9EAF-1D13374AEAA4Q36177985-B6E7F2B5-9529-4745-91CA-416EA973BDC9Q36370400-71F51DA2-0C03-4E95-A3A4-2575E2499065Q36902916-812B09E9-703D-490D-99B1-5F169486A304Q38633450-C64F9957-27D5-422C-8C67-2C64C386B276Q38708362-250D7C66-3D69-469E-92CF-0A244BFF0115Q38711698-B2DC31B3-A4AD-40AC-B76E-6ABBD56FF754Q40168402-3BD352A8-D041-48B0-B9AA-D1686B264D18Q40264319-4D9B6616-1C96-4655-ABB9-C19465C6866AQ40323063-9B9CB11C-BD42-4E8C-9534-5625BF904F3AQ40539777-16B35F87-23F3-44F0-8416-6A9D2375F6D5Q40833322-8677FF78-F71D-42EF-B62F-99BA8BE94F03Q41010354-71A51F7B-A95B-491E-B218-A085163D1986Q41038889-04CDAE9C-DC77-458E-97C8-3CC0CC19EC59Q41128217-ACD588C5-08B9-4D38-96D6-6BBEB166389CQ47678193-D07D1515-73E7-44C1-8D16-BD922D6D815DQ48523172-D9034373-33C7-4A67-9962-4F7C53591945Q51747338-24712FC2-762B-4FB7-8924-1934C5D9867CQ53187015-2D38AA0E-127E-4B77-A4F7-6FA16EAC8254Q58271057-C7B519BF-6CA9-484F-8107-B07BCB918F6FQ59133696-33C68924-130D-4933-9365-74CD3C9ECBA6
P2860
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
@en
type
label
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
@en
prefLabel
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
@en
P2093
P2860
P1476
Resistance of Candida spp. to antifungal drugs in the ICU: where are we now?
@en
P2093
Cécile Garnaud
Danièle Maubon
Muriel Cornet
P2860
P2888
P304
P356
10.1007/S00134-014-3404-7
P577
2014-08-05T00:00:00Z